Royalty Pharma plc
RPRX Health Care · No analyses yet
What changed
No articles about this company yet. Follow it to hear when the first one appears.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
| Company | Latest revenue | Revenue YoY | Operating margin |
|---|---|---|---|
| Royalty Pharma plc RPRX | — | — | — |
| Unitedhealth Group Inc UNH | $113B | -0.4% | 5.8% |
| Mckesson Corp MCK | $111B | +7.6% | 1.4% |
| CVS Health Corp CVS | $108B | +5.4% | 3.3% |
| Cigna Group CI | $73.7B | +5.6% | 3.3% |
| Cardinal Health Inc CAH | $67.5B | +5.5% | 1.1% |
| Elevance Health, Inc. ELV | $51.4B | +1.4% | 2.5% |
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|---|---|---|---|
| BlackRock | 27,832,977 | $1,560,595,060 | +7.4% | Q2 2026 |
| Fidelity (FMR) | 24,513,814 | $1,374,489,542 | -2.5% | Q2 2026 |
| State Street | 12,338,229 | $691,804,500 | +12.3% | Q2 2026 |
| Geode Capital Management | 8,058,048 | $450,581,226 | +2.4% | Q2 2026 |
| Norges Bank (Norway's sovereign fund) | 5,336,084 | $299,194,230 | — | Q2 2026 |
| Two Sigma Investments | 2,920,163 | $163,733,539 | +29.7% | Q2 2026 |
| Renaissance Technologies | 1,935,800 | $108,540,306 | +144.7% | Q2 2026 |
| Citadel Advisors | 1,354,640 | $75,954,665 | -49.5% | Q2 2026 |
| D. E. Shaw & Co. | 525,114 | $29,443,142 | -53.2% | Q2 2026 |
| Bridgewater Associates | 219,687 | $12,317,850 | — | Q2 2026 |
| Millennium Management | 12,043 | $675,251 | — | Q2 2026 |
| T. Rowe Price | 11,193,657 | $627,629 | +478.7% | Q2 2026 |
| Wellington Management | 7,105 | $398,377 | -0.4% | Q2 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.
